RSS-Feed abonnieren
DOI: 10.1055/s-0037-1604109
Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders—Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency
Publikationsverlauf
Publikationsdatum:
12. September 2017 (online)
![](https://www.thieme-connect.de/media/sth/201803/lookinside/thumbnails/10-1055-s-0037-1604109_02473-1.jpg)
Abstract
Intracranial hemorrhage (ICH) is a medical emergency. In congenital bleeding disorders, ICH is a devastating presentation accompanied with a high rate of morbidity and mortality. The prevalence of ICH is highly variable among congenital bleeding disorders, with the highest incidence observed in factor (F) XIII deficiency (FXIIID) (∼30%). This life-threatening presentation is less common in afibrinogenemia, FVIII, FIX, FVII, and FX deficiencies, and is rare in severe FV and FII deficiencies, type 3 von Willebrand disease and inherited platelet function disorders (IPFDs). In FXIIID, this diathesis most often occurs after trauma in children, whereas spontaneous ICH is more frequent in adults. About 15% of patients with FXIIID and ICH die; the bleeding causes 80% of deaths in this coagulopathy. Although in FXIIID, the bleed most commonly is intraparenchymal (> 90%), epidural, subdural, and subarachnoid hemorrhages also have been reported, albeit rarely. As this life-threatening bleeding causes neurological complications, early diagnosis can prevent further expansion of the hematoma and secondary damage. Neuroimaging plays a crucial role in the diagnosis of ICH, but signs and symptoms in patients with severe FXIIID should trigger replacement therapy even before establishment of the diagnosis. Although a high dose of FXIII concentrate can reduce the rate of morbidity and mortality of ICH in FXIIID, it may occasionally trigger inhibitor development, thus complicating ICH management and future prophylaxis. Nevertheless, replacement therapy is the mainstay of treatment for ICH in FXIIID. Neurosurgery is performed in patients with FXIIID and epidural hematoma and a hemorrhage diameter exceeding 2 cm or a volume of ICH is more than 30 cm3. Contact sports are not recommended in people with FXIIID as they can elicit ICH. However, a considerable number of safe sports and activities have been suggested to have more benefits than dangers for patients with congenital bleeding disorders, and are hence suitable for these patients.
-
References
- 1 Darby SC, Kan SW, Spooner RJ. , et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110 (03) 815-825
- 2 Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006; 4 (01) 19-25
- 3 Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21 (04) 388-393
- 4 Singleton TC, Keane M. Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review. Ochsner J 2012; 12 (03) 249-253
- 5 Kidwell CS, Wintermark M. Imaging of intracranial haemorrhage. Lancet Neurol 2008; 7 (03) 256-267
- 6 Caceres JA, Goldstein JN. Intracranial hemorrhage. Emerg Med Clin North Am 2012; 30 (03) 771-794
- 7 Caceres AJ, Greer DM, Goldstein JN. , et al. Enrollment of research subjects through telemedicine networks in a multicenter acute intracerebral hemorrhage clinical trial: design and methods. J Vasc Interv Neurol 2013; 6 (01) 1-6
- 8 Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30 (06) 461-475
- 9 Dorgalaleh A, Naderi M, Hosseini MS. , et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost 2015; 41 (03) 323-329
- 10 Mayer SA, Brun NC, Begtrup K. , et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358 (20) 2127-2137
- 11 Rick ME, Walsh CE, Key NS. Congenital bleeding disorders. Hematology (Am Soc Hematol Educ Program) 2003; 2003 (01) 559-574
- 12 Dorgalaleh A, Alavi SE, Tabibian S. , et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology 2017; 22 (04) 224-230
- 13 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455
- 14 Siddique H, Zafar T, Anwar T, Yaqoob N. Intracranial haemorrhage in patients with congenital bleeding disorders. J Rawalpindi Medical College 2014; 18 (01) 107-109
- 15 Giraldi C, Creta S, Martini A, Ioppoli C, Valleriani A, Muratorio A. Spontaneous intracerebral hematoma in a adolescent with factor XIII deficiency. Case report. Ital J Neurol Sci 1989; 10 (06) 579-582
- 16 Patiroglu T, Ozdemir MA, Unal E. , et al. Intracranial hemorrhage in children with congenital factor deficiencies. Childs Nerv Syst 2011; 27 (11) 1963-1966
- 17 Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008; 140 (04) 378-384
- 18 Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23 (06) 267-274
- 19 Bolton-Maggs PH, Perry DJ, Chalmers EA. , et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (05) 593-628
- 20 Siboni SM, Zanon E, Sottilotta G. , et al. Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia 2012; 18 (01) 34-38
- 21 Dorgalaleh A, Tabibian S, Shamsizadeh M. Inherited platelet function disorders (IPFDs). Clin Lab 2017; 63 (01) 1-13
- 22 Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 2011; 37 (06) 673-681
- 23 Naderi M, Alizadeh S, Kazemi A. , et al. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases. Hematology 2015; 20 (02) 112-118
- 24 Naderi M, Dorgalaleh A, Alizadeh S. , et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (05) 443-449
- 25 Davies J, Kadir RA. Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta-analysis of the literature. Haemophilia 2016; 22 (01) 32-38
- 26 Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999; 21 (04) 289-295
- 27 Nagel K, Pai MK, Paes BA, Chan AK. Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagul Fibrinolysis 2013; 24 (01) 23-27
- 28 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
- 29 American Academy of Pediatrics: Committee on Child Abuse and Neglect. Shaken baby syndrome: rotational cranial injuries-technical report. Pediatrics 2001; 108 (01) 206-210
- 30 Dorgalaleh A, Tabibian S, Hosseini MS. , et al. Diagnosis of factor XIII deficiency. Hematology 2016; 21 (07) 430-439
- 31 Dorgalaleh A, Tabibian S, Hosseini S, Shamsizadeh M. Guidelines for laboratory diagnosis of factor XIII deficiency. Blood Coagul Fibrinolysis 2016; 27 (04) 361-364
- 32 Muszbek L, Katona É. Diagnosis and management of congenital and acquired FXIII deficiencies. Semin Thromb Hemost 2016; 42 (04) 429-439
- 33 Carcao M, Fukutake K, Inbal A. , et al. Developing the first recombinant factor XIII for congenital factor XIII deficiency: clinical challenges and successes. Semin Thromb Hemost 2016; 43 (01) 59-68
- 34 de Moerloose P, Schved JF, Nugent D. Rare coagulation disorders: fibrinogen, factor VII and factor XIII. Haemophilia 2016; 22 (Suppl. 05) 61-65
- 35 Lak M, Peyvandi F, Ali Sharifian A, Karimi K, Mannucci PM. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1 (08) 1852-1853
- 36 Ivaskevicius V, Seitz R, Kohler HP. , et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
- 37 Duckert F. The fibrin stabilizing factor, factor XIII. Blut 1973; 26 (03) 177-179
- 38 Shetty S, Shelar T, Mirgal D. , et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 2014; 20 (04) 575-581
- 39 Naderi M, Zarei T, Haghpanah S, Eshghi P, Miri-Moghaddam E, Karimi M. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. Ann Hematol 2014; 93 (04) 693-697
- 40 Fadoo Z, Merchant Q, Rehman KA. New developments in the management of congenital Factor XIII deficiency. J Blood Med 2013; 4 (02) 65-73
- 41 Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006; 5 (01) 53-63
- 42 Mendelow AD. Mechanisms of ischemic brain damage with intracerebral hemorrhage. Stroke 1993; 24 (12, Suppl): I115-I117 , discussion I118–I119
- 43 Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344 (19) 1450-1460
- 44 Ryu S-J. Intracranial hemorrhage in patients with polycystic kidney disease. Stroke 1990; 21 (02) 291-294
- 45 Sahni R, Weinberger J. Management of intracerebral hemorrhage. Vasc Health Risk Manag 2007; 3 (05) 701-709
- 46 Toyoda K, Anderson CS, Mayer SA. New insights in intracerebral hemorrhage. Neuroepidemiology 2015; 45 (03) 139-236
- 47 Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009; 373 (9675): 1632-1644
- 48 Aguilar MI, Brott TG. Update in intracerebral hemorrhage. Neurohospitalist 2011; 1 (03) 148-159
- 49 de Oliveira Manoel AL, Goffi A, Zampieri FG. , et al. The critical care management of spontaneous intracranial hemorrhage: a contemporary review. Crit Care 2016; 20 (01) 272
- 50 Dorgalaleh A, Tabibian S, Shams M, Tavasoli B, Gheidishahran M, Shamsizadeh M. Laboratory diagnosis of factor XIII deficiency in developing countries: an Iranian experience. Lab Med 2016; 47 (03) 220-226
- 51 Naderi M, Karimi M, Hosseini MS, Moradi EH, Shamsizadeh M, Dorgalaleh A. Long term follow up study on a large group of patients with congenital factor XIII deficiency treated prophylactically with Fibrogammin P®. Iran J Pharm Res 2016; 15 (02) 635-640
- 52 Dorgalaleh A, Dadashizadeh G, Bamedi T. Hemophilia in Iran. Hematology 2016; 21 (05) 300-310
- 53 Chabrol B, Decarie J-C, Fortin G. The role of cranial MRI in identifying patients suffering from child abuse and presenting with unexplained neurological findings. Child Abuse Negl 1999; 23 (03) 217-228
- 54 Radcliffe WB, Guinto Jr FC, Adcock DF, Krigman MR. Subdural hematoma shape. A new look at an old concept. Am J Roentgenol Radium Ther Nucl Med 1972; 115 (01) 72-77
- 55 Kulkarni R, Ponder KP, James AH. , et al. Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a white paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia 2006; 12 (03) 205-211
- 56 Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001; 112 (02) 264-274
- 57 Witmer CM, Manno CS, Butler RB, Raffini LJ. The clinical management of hemophilia and head trauma: a survey of current clinical practice among pediatric hematology/oncology physicians. Pediatr Blood Cancer 2009; 53 (03) 406-410
- 58 Anderson A, Forsyth A. Playing It Safe: Bleeding Disorders, Sports and Exercise. New York, NY: National Hemophilia Foundation; 2005: 44
- 59 Rice SG. ; American Academy of Pediatrics Council on Sports Medicine and Fitness. Medical conditions affecting sports participation. Pediatrics 2008; 121 (04) 841-848
- 60 Mulder K, Cassis F, Seuser DR, Narayan P, Dalzell R, Poulsen W. Risks and benefits of sports and fitness activities for people with haemophilia. Haemophilia 2004; 10 (Suppl. 04) 161-163
- 61 Brown DL. Congenital bleeding disorders. Curr Probl Pediatr Adolesc Health Care 2005; 35 (02) 38-62
- 62 Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130 (Suppl. 02) S12-S14
- 63 Badenes R, Bilotta F. Neurocritical care for intracranial haemorrhage: a systematic review of recent studies. Br J Anaesth 2015; 115 (Suppl. 02) ii68-ii74
- 64 Ribizzi G, Farinini D, Gentile R, Rizzi D, Serrati C. Factor XIII deficiency and head trauma: management and therapy. Neurol Sci 2015; 36 (10) 1933-1934
- 65 Little KM, Alexander MJ. Medical versus surgical therapy for spontaneous intracranial hemorrhage. Neurosurg Clin N Am 2002; 13 (03) 339-347
- 66 Albanese A, Tuttolomondo A, Anile C. , et al. Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases. J Neurosurg 2005; 102 (06) 1130-1132
- 67 Pernod G, Barro C, Arnutti B. , et al. Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review. Haemophilia 2003; 9 (01) 121-124
- 68 Vural M, Yarar C, Durmaz R, Atasoy MA. Spontaneous acute subdural hematoma and chronic epidural hematoma in a child with F XIII deficiency. J Emerg Med 2010; 38 (01) 25-29